The PAH gene makes an enzyme in the liver that converts the amino acid phenylalanine into tyrosine. This gene plays an important role in keeping phenylalanine from building up in the blood. If PAH does not work, high phenylalanine can cause phenylketonuria (PKU), which can affect brain development and learning without early treatment. PAH is widely recognized because PKU is included in routine newborn screening, and diet-based treatment started in infancy can support healthy growth.
What is a gene?
Genes are stretches of DNA that carry instructions your cells use to make molecules or manage activities in the body. In some cases, a gene provides the directions for producing proteins, which act as the cell’s main working components. Other genes are more focused on regulating which processes are active, where they happen, and how strongly they operate. Taken together, genes help guide growth and everyday body function, and they can influence how you react to food, stress, or medications. More detailed information is available in the LearnHub.
Overview
PAHGene function
What if the gene works
The PAH gene helps your liver make an enzyme that converts the amino acid phenylalanine into tyrosine. This keeps phenylalanine levels in a safe range and supports normal brain development and function.
Risk
What if the gene does not work
When the PAH gene does not work well, phenylalanine can build up in the blood, and without treatment this can affect brain development, learning, mood, and seizures. DNA changes range from mild hyperphenylalaninemia to classic phenylketonuria, influencing timing and severity.
Treatment
What does that mean for your treatment
PAH variants can help predict whether sapropterin (BH4) is likely to work, because only some changes leave enough enzyme activity to respond. If levels stay high despite diet and sapropterin, pegvaliase can be an option to lower phenylalanine.
Conditions associated with PAH
Gene function
What if the gene works
After you eat protein foods, your body needs to handle the amino acid phenylalanine in a controlled way. In many people, the PAH gene supports this routine step of metabolism, mainly in the liver. When it is working properly, phenylalanine is efficiently processed and key building blocks are kept available for normal body functions.
The PAH gene provides instructions for an enzyme that converts phenylalanine into another amino acid. This helps your body keep phenylalanine levels steady after everyday meals that contain protein.
By changing phenylalanine into tyrosine, this gene helps maintain a steady supply of tyrosine for normal body chemistry. This part of PAH gene function supports typical protein building and other tyrosine-dependent processes in many tissues.
The PAH enzyme works with a helper molecule called tetrahydrobiopterin (BH4), which helps the reaction run smoothly. This teamwork supports efficient amino acid handling as part of day-to-day liver metabolism.
What is a variant?
A genetic variant is a minor difference in a gene’s DNA sequence. These differences happen often and help explain everyday human variation, such as changes in appearance, metabolism, or the way the body reacts to environmental factors. Many variants do not cause any noticeable changes and are part of normal genetic diversity. In certain situations, though, a variant can affect how a gene works more significantly and may play a role in, or lead to, a genetic condition.
Genetic variants
What if the gene does not work
Changes in the PAH gene can reduce how well the body breaks down phenylalanine, an amino acid from protein foods. Depending on the specific PAH gene mutation, the gene may still work partly (milder variants) or have little to no activity (more severe mutations), which can lead to mild high phenylalanine levels or phenylketonuria (PKU). This range can shape how early problems appear, how strict diet treatment needs to be, and which health and learning features show up.
How variants are linked to conditions
Variants in the PAH gene are strongly linked to phenylketonuria (PKU) and milder forms of hyperphenylalaninemia, conditions identified by higher-than-expected phenylalanine levels, often found through newborn screening. Different PAH gene variants can be associated with a range of severity, from mild forms to classic PKU, and having two disease-causing variants can confirm the diagnosis. People who carry one disease-causing PAH gene variant are usually healthy carriers.
A variant is not necessarily a diagnosis
Differences in DNA are expected in people and show up frequently across the population. In most cases, these genetic variants do not directly change health and instead reflect normal human diversity. For many genes, a variant that has been connected with a condition indicates a potential link rather than a certain diagnosis, particularly when several genes and environmental influences contribute. In other situations, though, one clearly defined variant in a particular gene can be enough to confirm a diagnosis.
Are there things that can increase or change my risk?
With PAH changes that cause PKU, the gene effect is the main driver, so lifestyle can’t remove the condition. Risk of brain and nerve problems rises when blood phenylalanine stays high, such as with a higher-protein diet, missed medical formula, or during illness. Pregnancy with high levels can harm a baby, so tight control matters.
Inheritance of PAH variants
The PAH gene inheritance pattern is autosomal recessive. You inherit one PAH gene copy from each parent, so a condition occurs when both copies have a disease-causing variant; parents are often healthy carriers. When both parents are carriers, each pregnancy has a 25% chance of an affected child, a 50% chance of a carrier child, and a 25% chance of a child with no variant.
What does my PAH result mean for my family?
If your PAH result shows a change that can cause phenylketonuria (PKU), share it with close relatives because it can run in families and may affect pregnancy planning or newborn care. Seek medical advice if there is a family history of PKU, learning or behavior concerns, seizures, or a musty body odor, or if a baby is not feeding or growing well. Also ask if diet treatment or sapropterin could be relevant, since some PAH changes respond differently.
Genetic information
Genetic testing
How you find out about variants
A blood or saliva sample can be used for PAH gene genetic testing to look for changes linked to phenylalanine hydroxylase deficiency (phenylketonuria, PKU). Labs read the DNA sequence and compare it with a reference, then report variants as pathogenic, likely pathogenic, uncertain, likely benign, or benign.
When should I consider getting a genetic test?
Consider PAH genetic testing if newborn screening shows high phenylalanine (a building block from protein) or if a child has signs of phenylketonuria (PKU), such as developmental delays or musty body odor. Testing also makes sense if PKU runs in your family or if you and your partner want to know your chance of having a child with PKU.
A genetic result is only one part of your health story
Genetic test findings can be very informative, but what they can tell you varies with the health condition and the specific type of variant found. How your body functions and changes across time is also shaped by many other factors, including your lifestyle, environment, age, and medical history. With some conditions, particularly those affected by many genes, genetic information provides added background rather than a definite prediction and makes the most sense when viewed together with other parts of your care. In other situations, a genetic result can be more straightforward and give a clear answer. For topics like how you respond to certain medications, genetic results can help put your personal experiences into context.
Pharmacogenetics
How variants shape your response to medicine
Variants in the PAH gene can influence how well certain treatments for phenylalanine processing problems work, including whether someone with phenylketonuria may respond to sapropterin (a medicine that can help some people lower phenylalanine levels). Different PAH gene changes can leave different amounts of enzyme activity, which can affect how much benefit a medicine provides. This kind of genetic influence on medication response is common across many conditions, because genes help shape how the body handles and reacts to treatments. Genetics is only one piece of the picture, and factors like age, diet, other health conditions, and other medicines can also affect results.
What is Pharmacogenetics?
Pharmacogenetics examines the ways genetic variation can affect how a person responds to medications. It focuses on relationships between specific genes and particular drugs to help explain why the same treatment may not work the same for everyone. For many medicines, your genes can influence how powerfully a drug works or how your body handles it. This information can support more informed choices and a more individualized approach to treatment. More details are available in the LearnHub if you would like to learn more.
Drugs influenced by the PAH gene
When should I seek medical advice?
Seek medical advice if you or your child has been told there are high levels of phenylalanine (an amino acid in protein) or phenylketonuria (PKU), or if treatment feels hard to follow and symptoms like poor feeding, vomiting, unusual sleepiness, or developmental delays show up. Get medical guidance before major diet changes, using medical foods or supplements, or starting a new medicine. If you’re pregnant or planning pregnancy and have PKU, early care is important.
History
Phenylketonuria (PKU), the condition most closely linked to the PAH gene, was first recognized in 1934 when Norwegian physician Asbjørn Følling connected a distinctive urine odor with developmental differences in children. From these first observations, research expanded steadily. In the 1950s, doctors showed that a carefully managed low phenylalanine diet could improve outcomes, changing PKU from a condition recognized after symptoms appeared into one that could be treated early. In the early 1960s, Robert Guthrie’s newborn blood spot screening test helped make routine newborn screening possible in many countries. During the 1980s, researchers identified and mapped the PAH gene, which opened the door to more precise genetic testing and clearer variant-based diagnosis.